➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Merck
AstraZeneca
Baxter
Medtronic

Last Updated: September 26, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for BGB-3111


Email this page to a colleague

« Back to Dashboard

What is the drug development status for BGB-3111?

BGB-3111 is an investigational drug.

There have been 97 clinical trials for BGB-3111. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2018.

The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Carcinoma. The leading clinical trial sponsors are BeiGene, BeiGene USA, Inc., and German CLL Study Group.

There are seven US patents protecting this investigational drug and sixty international patents.

Recent Clinical Trials for BGB-3111
TitleSponsorPhase
A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in Patients With B-Cell MalignanciesBeiGenePhase 1
Treatment of Relapsed/Refractory Multiple Myeloma With t 11;14 Translocation Using BGB-11417 With Dexamethasone; Also Using BGB-11417 in Combination With Dexamethasone and Carfilzomib.BeiGenePhase 1/Phase 2
Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung CancerBeiGenePhase 2

See all BGB-3111 clinical trials

Clinical Trial Summary for BGB-3111

Top disease conditions for BGB-3111
Top clinical trial sponsors for BGB-3111

See all BGB-3111 clinical trials

US Patents for BGB-3111

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
BGB-3111 ⤷  Free Forever Trial Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators BEIGENE, LTD. (Grand Cayman, KY) ⤷  Free Forever Trial
BGB-3111 ⤷  Free Forever Trial Treatment of pemphigus PRINCIPIA BIOPHARMA INC. (South San Francisco, CA) ⤷  Free Forever Trial
BGB-3111 ⤷  Free Forever Trial Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators BEIGENE SWITZERLAND GMBH (Basel, CH) ⤷  Free Forever Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
McKesson
Colorcon
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.